{
    "clinical_study": {
        "@rank": "168035", 
        "arm_group": [
            {
                "arm_group_label": "HP001", 
                "arm_group_type": "Experimental", 
                "description": "powder type, 3 times per day before the meal, 12 weeks total"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "powder type, 3 times per day before the meal, 12 weeks total"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this study is obese patient with HP001 for 12 weeks will show a superior\n      reduction compared to those taking the placebo."
        }, 
        "brief_title": "Evaluating the Safety and Efficacy of HP001 on Obesity", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "This study has two arms, HP001 and placebo group. Inclusion of 80 patient each arm. They\n      will be screened at first visit. At the baseline, that is the second visit, they will be\n      evaluated each outcomes including weight, waist circumference, lipid profile (total\n      cholesterol, triglyceride), CRP (C-reactive protein), visceral fat area and subcutaneous fat\n      area using abdominal computed tomography (CT), questionnaires of QoL (Quality of Life) and\n      eating attitudes, etc. The HP001 will provide to the patients from the baseline, it contains\n      4 weeks of serving. After 4 weeks, the visit 3, the evaluation procedure will be repeated\n      except lipid profile, CRP, abdominal CT. Another HP001 of 4 weeks will be given to the\n      patient. The visit 4, 4 weeks after the visit 3, the same procedure will be repeated. The\n      visit 5, 12 weeks after from the baseline, the patient will be evaluated including weight,\n      waist circumference, lipid profile, CRP, visceral fat area and subcutaneous fat area using\n      abdominal computed tomography, questionnaires of QoL and eating attitudes, etc."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women aged 18-65 years old\n\n          2. Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI\n             27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled\n             (SBP \u2264 145mmHg, DBP \u2264 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent\n             diabetes mellitus and fasting blood glucose < 7.8mmol/L(140mg/dL) 2.4. BMI\n             27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and\n             Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening\n\n          3. Agreed to low-calorie diet during the trial\n\n          4. Written informed consent of the trial\n\n        Exclusion Criteria:\n\n          1. Endocrine disease such as hypothyroidism, Cushing's syndrome, etc.\n\n          2. Heart disease (heart failure, angina pectoris, myocardial infarction)\n\n          3. Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)\n\n          4. Malignant tumour or lung disease\n\n          5. Cholelithiasis\n\n          6. Severe renal disability (SCr > 2.0 mg/dL)\n\n          7. Severe liver disability (2.5 fold of normal high range value on Alanine\n             Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)\n\n          8. Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL)\n             or over\n\n          9. Narrow angle glaucoma\n\n         10. History or existence of neurological or psychological disease (schizophrenia,\n             epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)\n\n         11. History of stroke or temporary ischemic cardioplegia\n\n         12. History or existence of eating disorder such as anorexia nervosa or bulimia nervosa,\n             etc.\n\n         13. Use of medication that could have effect on weight within last 3 months (appetite\n             suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine,\n             phenothiazine or medication having effect on absorption, metabolism, excretion)\n\n         14. Use of \u03b2--blocker or diuretic as hypertension medication within last 3 months\n\n         15. Use of medication for central nervous system or central active weight reduction\n             medication\n\n         16. Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin\n             agent, barbiturate, antipsychotic, medication concerns of abuse)\n\n         17. Difficult to measure anthropometric dimensions because of anatomical change such as\n             resection\n\n         18. Surgical history for weight reduction; bariatric surgery, etc.\n\n         19. Unable to follow instructions of the trial as judged by investigator\n\n         20. Women who were pregnant, lactating, planning a pregnancy or women of childbearing age\n             who do not agree to proper contraception (birth-control pill, hormone implant, IUD,\n             spermicide, condom, abstinence, etc.) (Women of childbearing age indicate within 2\n             years of menopause who did not receive hysterectomy, bilateral tubal ligation,\n             bilateral oophorectomy, etc.)\n\n         21. Use of other investigational product within last 1 month\n\n         22. Reduction over 10% of the previous weight within 6 months\n\n         23. Decided to stop smoking within last 3 months; however, keeping irregular smoking\n             habit"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724099", 
            "org_study_id": "HP001"
        }, 
        "intervention": [
            {
                "arm_group_label": "HP001", 
                "description": "Korean medicinal herbal drug", 
                "intervention_name": "HP001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo drug, same odor and formula as HP001", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Herbal product", 
            "Korean Medicine"
        ], 
        "lastchanged_date": "November 8, 2012", 
        "location": {
            "contact": {
                "email": "oxygen@korea.com", 
                "last_name": "Yoon-kyung SONG, Doctor", 
                "phone": "070-7120-5046"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of", 
                    "zip": "405-760"
                }, 
                "name": "Gachon University Gil Medical Center"
            }, 
            "investigator": {
                "last_name": "Yoon-kyung SONG, KMD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of HP001 on Obese Patients", 
        "overall_contact": {
            "email": "khuksg@gmail.com", 
            "last_name": "Seong-gyu KO, KMD", 
            "phone": "82-2-961-9278"
        }, 
        "overall_official": {
            "affiliation": "Gachon University Medical Center", 
            "last_name": "Yoon-kyung SONG, KMD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Weight reduction", 
            "safety_issue": "No", 
            "time_frame": "between baseline and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724099"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kyunghee University Medical Center", 
            "investigator_full_name": "Seong-Gyu Ko", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "C-reactive protein (CRP)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 4 weeks, 8 weeks, and 12 weeks"
            }, 
            {
                "measure": "Blood glucose", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Waist/hip ratio", 
                "safety_issue": "No", 
                "time_frame": "4 weeks, 8 weeks, and 12 weeks"
            }, 
            {
                "measure": "Waist circumference", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 weeks, 8 weeks, and 12 weeks"
            }, 
            {
                "measure": "Korean Obesity-related Quality of Life scale", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Korean version of Eating Attitudes Test-26", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Triglyceride", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "description": "Using abdominal computed tomography", 
                "measure": "Visceral fat area", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "description": "Using abdominal computed tomography", 
                "measure": "Subcutaneous fat area", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }
        ], 
        "source": "Kyunghee University Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Korea Health Industry Development Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gachon University Gil Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Kyunghee University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}